Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) (Primary Study) — 96.2 percentage of participants…

Primary: Baseline 24-hour Average Systolic Blood Pressure (SBP) — 136.11; 133.13; 135.08; 135.59 mmHg

Primary: Roland Morris — 11.8; 12.5 units on a scale

Primary: Radiologic Evidence of Bone Healing — 12.6; 11.2; 15.4; 13.2 units on a scale

Primary: HbA1C (%) — 9.7; 10.0; 8.8; 8.0 Percentage of glycosylated hemoglobin

Primary: Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months — 0; 0 mm^3

Primary: Comfort — 8.2; 7.4 units on a scale

Primary: Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis — 60; 53; 45; 36 Participants

Primary: Randomized Cohort: OAB Therapeutic Response — 61; 42 percentage of participants with response — p=0.016

Primary: Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer — 80.1…

Primary: Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6 — 48.61; 9.33; 22.07; 3.8 Stimulation index

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 25; 19; 22; 4 Participants

Primary: Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain — 91; 48; 168; 75 Participants

Primary: Participant Clinical Benefit Response Rate — 15.1 percentage of participants

Primary: Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports — 37; 40; 28; 36 events